Seattle Genetics: Insider decken sich die letzten Wochen massiv ein... - 500 Beiträge pro Seite

[Homm13]

Insider kaufen in den letzten Wochen nach Erreichung eines Meilensteins (Zahlung von CuraGen) massiv Aktien. Bill Gates ist unter den Top 5 der institutionellen Aktienbesitzern.

TOP INSTITUTIONAL HOLDERS

Holder Shares % Out Value* Reported
BANK OF AMERICA CORPORATION 3,779,278 7.59 $19,501,074 31-Mar-06
GATES (BILL & MELINDA) FOUNDATION 3,521,088 7.07 $18,168,814 31-Mar-06
...

29-Jun-06 6:03 PM Baker Biotech Capital (GP), LLC
Director
10% Owner 20,340 Market Purchase 29-Jun-06 $4.08 $82,922.11 8% view
29-Jun-06 6:03 PM Baker Brothers Life Sciences Capital (GP), LLC
Director
10% Owner 61,443 Market Purchase 29-Jun-06 $4.08 $250,490.81 8% view
29-Jun-06 6:07 PM 14159 capital (GP), LLC
Director
10% Owner 1,317 Market Purchase 29-Jun-06 $4.08 $5,369.15 8% view
29-Jun-06 6:03 PM Baker Brothers Life Sciences Capital (GP), LLC
Director
10% Owner 233,645 Market Purchase 28-Jun-06 $4.02 $938,645.37 10% view
29-Jun-06 6:03 PM Baker Biotech Capital (GP), LLC
Director
10% Owner 77,345 Market Purchase 28-Jun-06 $4.02 $310,725.79 10% view
29-Jun-06 6:07 PM 14159 capital (GP), LLC
Director
10% Owner 5,010 Market Purchase 28-Jun-06 $4.02 $20,127.17 10% view
29-Jun-06 6:03 PM Baker Biotech Capital (GP), LLC
Director
10% Owner 32,297 Market Purchase 27-Jun-06 $4.04 $130,373.94 9% view
29-Jun-06 6:03 PM Baker Brothers Life Sciences Capital (GP), LLC
Director
10% Owner 97,745 Market Purchase 27-Jun-06 $4.04 $394,569.18 9% view
29-Jun-06 6:07 PM 14159 capital (GP), LLC
Director
10% Owner 2,108 Market Purchase 27-Jun-06 $4.04 $8,509.41 9% view
27-Jun-06 7:51 AM Baker Biotech Capital (GP), LLC
Director
10% Owner 34,216 Market Purchase 26-Jun-06 $4.00 $136,918.74 10% view
27-Jun-06 7:50 AM Baker Brothers Life Sciences Capital (GP), LLC
Director
10% Owner 103,552 Market Purchase 26-Jun-06 $4.00 $414,373.66 10% view
27-Jun-06 7:49 AM 14159 capital (GP), LLC
Director
10% Owner 2,232 Market Purchase 26-Jun-06 $4.00 $8,931.57 10% view
27-Jun-06 7:49 AM 14159 capital (GP), LLC
Director
10% Owner 563 Market Purchase 23-Jun-06 $4.07 $2,289.95 9% view
27-Jun-06 7:51 AM Baker Biotech Capital (GP), LLC
Director
10% Owner 8,639 Market Purchase 23-Jun-06 $4.07 $35,138.27 9% view
27-Jun-06 7:50 AM Baker Brothers Life Sciences Capital (GP), LLC
Director
10% Owner 26,145 Market Purchase 23-Jun-06 $4.07 $106,342.17 9% view
27-Jun-06 7:51 AM Baker Biotech Capital (GP), LLC
Director
10% Owner 7,680 Market Purchase 22-Jun-06 $4.06 $31,142.86 9% view
27-Jun-06 7:50 AM Baker Brothers Life Sciences Capital (GP), LLC
Director
10% Owner 23,244 Market Purchase 22-Jun-06 $4.06 $94,255.81 9% view
27-Jun-06 7:49 AM 14159 capital (GP), LLC
Director
10% Owner 502 Market Purchase 22-Jun-06 $4.06 $2,035.64 9% view
21-Jun-06 6:26 PM Baker Brothers Life Sciences Capital (GP), LLC
Director
10% Owner 36,983 Market Purchase 21-Jun-06 $4.07 $150,642.85 9% view
21-Jun-06 6:21 PM Baker Biotech Capital (GP), LLC
Director
10% Owner 12,220 Market Purchase 21-Jun-06 $4.07 $49,775.72 9% view
21-Jun-06 6:25 PM 14159 capital (GP), LLC
Director
10% Owner 797 Market Purchase 21-Jun-06 $4.07 $3,246.42 9% view
21-Jun-06 6:25 PM 14159 capital (GP), LLC
Director
10% Owner 1,052 Market Purchase 20-Jun-06 $3.99 $4,201.37 11% view
21-Jun-06 6:21 PM Baker Biotech Capital (GP), LLC
Director
10% Owner 16,117 Market Purchase 20-Jun-06 $3.99 $64,366.30 11% view
21-Jun-06 6:26 PM Baker Brothers Life Sciences Capital (GP), LLC
Director
10% Owner 48,776 Market Purchase 20-Jun-06 $3.99 $194,796.22 11% view
21-Jun-06 6:25 PM 14159 capital (GP), LLC
Director
10% Owner 645 Market Purchase 19-Jun-06 $4.00 $2,578.36 11% view
21-Jun-06 6:21 PM Baker Biotech Capital (GP), LLC
Director
10% Owner 9,895 Market Purchase 19-Jun-06 $4.00 $39,554.77 11% view
21-Jun-06 6:26 PM Baker Brothers Life Sciences Capital (GP), LLC
Director
10% Owner 29,946 Market Purchase 19-Jun-06 $4.00 $119,707.64 11% view
13-Jun-06 9:41 PM Baker Brothers Life Sciences Capital (GP), LLC
Director
10% Owner 87,236 Market Purchase 13-Jun-06 $4.00 $349,031.23 10% view
13-Jun-06 9:43 PM Baker Biotech Capital (GP), LLC
Director
10% Owner 28,825 Market Purchase 13-Jun-06 $4.00 $115,328.82 10% view
13-Jun-06 9:44 PM 14159 capital (GP), LLC
Director
10% Owner 1,881 Market Purchase 13-Jun-06 $4.00 $7,525.84 10% view
13-Jun-06 9:44 PM 14159 capital (GP), LLC
Director
10% Owner 31,197 Market Purchase 09-Jun-06 $4.00 $124,915.90 10% view
13-Jun-06 9:41 PM Baker Brothers Life Sciences Capital (GP), LLC
Director
10% Owner 1,447,210 Market Purchase 09-Jun-06 $4.00 $5,794,773.34 10% view
13-Jun-06 9:43 PM Baker Biotech Capital (GP), LLC
Director
10% Owner 478,196 Market Purchase 09-Jun-06 $4.00 $1,914,744.53 10% view
25-May-06 9:48 AM Baker Biotech Capital (GP), LLC
Director
10% Owner 278,650 Purchase 24-May-06 $5.25 $1,462,912.50 -- view
25-May-06 9:51 AM 14159 capital (GP), LLC
Director
10% Owner 18,230 Purchase 24-May-06 $5.25 $95,707.50 -- view
25-May-06 9:55 AM Baker Brothers Life Sciences Capital (GP), LLC
Director
10% Owner 832,135 Purchase 24-May-06 $5.25 $4,368,708.75 -- view

...



"ADCs have the potential to transform the field of antibody-based therapies by further enhancing the therapeutic efficacy of monoclonal antibodies for treatment of cancer and other serious diseases," said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. "We continue to make significant advances with our ADC technology, as demonstrated both by this milestone under our collaboration with CuraGen, as well as progress with our internal ADC programs, including our planned IND filing for SGN-35 in mid-2006."


Hier die Homepage:
http://www.seattlegenetics.com/


Interessierte Anleger können sich diesen Wert mal genauer unter die LUPE nehmen

[Homm13]

Allein die Allianzen sind sehenswert

http://www.seattlegenetics.com/about/alliances.htm



















PSMA Development

Company


Seattle Genetics has licensed its antibody-drug conjugate (ADC) technology to Genentech, Bayer, MedImmune, CuraGen, PSMA Development Company, PDL BioPharma and UCB Celltech for use with their proprietary monoclonal antibodies. These collaborations all involve upfront cash payments, milestones and royalties on net sales of products incorporating Seattle Genetics' ADC technology. The licensees are responsible for development, manufacturing and commercialization of any ADC product candidates that result from the collaborations.

Co-Development Agreement




Seattle Genetics has a co-development agreement with Celera Genomics to jointly discover and develop antibody-based therapies for cancer. Products developed under the collaboration may include either monoclonal antibodies or antibodies linked to potent cell-killing payloads utilizing Seattle Genetics’ ADC technology.

In-Licenses

A key part of Seattle Genetics' strategy is to in-license antibodies and other technology from companies and academic institutions.




In 1998, Seattle Genetics in-licensed a large portfolio of intellectual property in the monoclonal antibody-targeting area from Bristol-Myers Squibb as the initial building block of the company. This technology included rights to 26 issued patents, eight monoclonal antibodies, chemical linkers and other enabling technologies. Seattle Genetics also received cGMP supplies of SGN-15, which is presently in clinical trials.




Seattle Genetics has a license agreement with ICOS Corporation for non-exclusive rights to use ICOS' CHEF1 expression system to develop and manufacture SGN-30 and other mAbs. ICOS has conducted cGMP manufacturing of the monoclonal antibody component of SGN-15 and the monoclonal antibody product candidate SGN-30.




Seattle Genetics licensed from PDL BioPharma exclusive rights to its anti-CD33 program, including associated U.S. patents and patent applications, supplies of clinical grade material and a non-exclusive CD33 license under PDL BioPharma's antibody humanization patents. Separately, we obtained one license and options for two additional licenses under PDL BioPharma's antibody humanization patents. We have used the initial antibody humanization license for our SGN-40 product candidate.

Seattle Genetics has also in-licensed technologies from the following companies and academic institutions, among others:

University of Miami

Arizona State University

Mabtech AB

CLB Research and Development

[Homm13]

Antwort auf Beitrag Nr.: 22.443.770 von Homm13 am 07.07.06 00:47:04

Peter Lynch sagte schon...

"insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"

Na dann...